Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma

Clinical Lymphoma and Myeloma

Volumn 6, Issue 6, 2006, Pages 469-474

  Barlogie, Bart ^a   Zangari, Maurizio ^a   Bolejack, Vanessa ^b   Hollmig, Klaus ^a   Anaissie, Elias ^a   van Rhee, Frits ^a   Pineda Roman, Mauricio ^a   Mohiuddin, Abid ^a   Crowley, John ^a   Tricot, Guido ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Chemotherapy; Cytogenetic abnormality; Hypodiploidy; Immunomodulatory agents; Total Therapy

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; MELPHALAN; MESNA; THALIDOMIDE; VINCRISTINE;

AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DIPLOIDY; GENE DELETION; GENETIC DISORDER; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME;

EID: 33745916115     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.027     Document Type: Article

References (23)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335:91-97.
2. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-1883.
3. Bladé J, Rosiñol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106:3755-3759.
4. Barlogie B, Kyle R, Anderson K, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup trial S9321. J Clin Oncol 2006; 24:929-936.
5. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349:2495-2502.
6. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93:55-65.
7. Barlogie B, Tricot G, O'Shaughnessy J, et al. Effect of adding thalidomide to the treatment of multiple myeloma with tandem hematopoietic cell autotransplants. N Eng J Med. In press.
8. Blade J, Samson D, Reece D, et al. Criteria for evaluating response in pateients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation. Br J Haematol 1998; 102:1115-1123.
9. Kaplan EL, Meier R. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-458.
10. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-170.
11. Cox DR. Regression models and life tables. J R Statist Soc 1972; B34:187-202.
12. Durie BGM, Jacobson J, Barlogie B, et al. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group chemotherapy trials. J Clin Oncol 2004; 22:1857-1863.
13. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma, N Engl J Med 1999; 341:1565-1571.
14. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100:3063-3067.
15. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-2617.
16. Rajkumar SV, Jayman SR, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20:4319-4323.
17. Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple mycloma. J Clin Oncol 2003; 21:16-19.
18. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106:35-39.
19. Jagannath S, Durie B, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129:776-783.
20. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (REV/DEX for newly diagnosed myeloma). Blood 2005; 106:4050-4053.
21. Palumbo A, Bertola A, Musto P, et al. A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): an interim analysis. Blood 2004; 104:207.
22. Oakervee H, Popat R, Curry N, et al. PAD combination therapy (PS341/ bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129:755-762.
23. Orlowki R, Voorhees P, Garcia R, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105:3058-3065.